Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas

Journal of Nuclear Medicine

Volumn 54, Issue 7, 2013, Pages 1032-1038

  Ryu, In Sun ^a   Kim, Jae Seung ^a   Roh, Jong Lyel ^a   Lee, Jeong Hyun ^a   Cho, Kyung Ja ^a   Choi, Seung Ho ^a   Nam, Soon Yuhl ^a   Kim, Sang Yoon ^a,b  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

Author keywords

18F FDG PET CT; Metabolic tumor volume; Prognostic factors; Salivary gland carcinomas; Total lesion glycolysis

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER TOMOGRAPHY SCANNER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH VESSEL METASTASIS; MALE; METABOLIC TUMOR VOLUME; ONCOLOGICAL PARAMETERS; ORAL SURGERY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERINEURAL INVASION; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFERENCE VALUE; SALIVARY GLAND CARCINOMA; TOTAL LESION GLYCOLYSIS;

18F-FDG PET/CT; METABOLIC TUMOR VOLUME; PROGNOSTIC FACTORS; SALIVARY GLAND CARCINOMAS; TOTAL LESION GLYCOLYSIS;

ADOLESCENT; ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; GLYCOLYSIS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SALIVARY GLAND NEOPLASMS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 84879909050     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.116053     Document Type: Article

References (32)

1. Pinkston JA, Cole P. Incidence rates of salivary gland tumors: results from a population-based study. Otolaryngol Head Neck Surg. 1999;120:834-840.
2. Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg. 1986;8:177-184.
3. Barnes LEJ, Reichart P, Sidransky D. World Health Organization classification of tumours. In: Pathology and Genetics: Head and Neck Tumours. Lyon, France: IARC Press; 2005:209-281.
4. Bell RB, Dierks EJ, Homer L, Potter BE. Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg. 2005;63: 917-928.
5. Kokemueller H, Swennen G, Brueggemann N, Brachvogel P, Eckardt A, Hausamen JE. Epithelial malignancies of the salivary glands: clinical experience of a single institution - a review. Int J Oral Maxillofac Surg. 2004;33: 423-432.
6. Lima RA, Tavares MR, Dias FL, et al. Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol Head Neck Surg. 2005;133:702-708.
7. Armstrong JG, Harrison LB, Spiro RH, Fass DE, Strong EW, Fuks ZY. Malignant tumors of major salivary gland origin: a matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg. 1990;116:290-293.
8. Chen AM, Granchi PJ, Garcia J, Bucci MK, Fu KK, Eisele DW. Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 2007;67:982-987.
9. Terhaard CHJ, Lubsen H, Rasch CR, et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys. 2005;61:103-111.
10. Minn H, Clavo AC, Grenman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med. 1995;36:252-258.
11. Haberkorn U, Strauss LG, Reisser C, et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med. 1991;32:1548-1555.
12. Menda Y, Graham MM. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers. Semin Nucl Med. 2005;35:214-219.
13. Jeong HS, Chung MK, Son YI, et al. Role of 18F-FDG PET/CT in management of high-grade salivary gland malignancies. J Nucl Med. 2007;48:1237-1244.
14. Branstetter BF, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology. 2005;235:580-586.
15. Lonneux M, Hamoir M, Reychler H, et al. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol. 2010;28:1190-1195.
16. Lee P, Weerasuriya DK, Lavori PW, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69:328-333.
17. Chung MK, Jeong HS, Park SG, et al. Metabolic tumor volume of [F-18]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15:5861-5868.
18. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264:559-566.
19. Green FL, Page DL, Fleming ID, Fritz A, Balch CM. American Joint Committee on Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002: 69-75.
20. Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159-171.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
22. Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978;8:283-298.
23. Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [18F] fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20:4199-4208.
24. Ryan WR, Fee WE Jr., Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope. 2005;115:645-650.
25. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine- 18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med. 1997; 38:1907-1911.
26. Otsuka H, Graham MM, Kogame M, Nishitani H. The impact of FDG-PET in the management of patients with salivary gland malignancy. Ann Nucl Med. 2005;19:691-694.
27. Roh JL, Ryu CH, Choi SH, et al. Clinical utility of 18F-FDG PET for patients with salivary gland malignancies. J Nucl Med. 2007;48:240-246.
28. Razfar A, Heron DE, Branstetter BF, Seethala RR, Ferris RL. Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. Laryngoscope. 2010;120:734-738.
29. Hadiprodjo D, Ryan T, Truong MT, Mercier G, Subramaniam RM. Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters. AJR. 2012;198:W185-W190.
30. Romesser PB, Qureshi MM, Shah BA, et al. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensitymodulated radiotherapy. Ann Nucl Med. 2012;26:527-534.
31. Machtay M, Natwa M, Andrei J, et al. Pretreatment PDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck. 2009;31:195-201.
32. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[F-18]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295-1300.